Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

THERATOPE

Known as: THERATOPE STn-KLH vaccine 
National Institutes of Health

Related topics

Related topics

2 relations
cyclophosphamide/THERATOPE STn-KLH vaccinesialyl-Tn antigen-keyhole-limpet hemocyanin conjugate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
Vaccination with Theratope® (STn-KLH) as treatment for breast cancer
Cancer vaccines have demonstrated that they can stimulate antibody and cell-mediated immune responses against tumor-associated… Expand
Review
2003
Review
2003
Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
Mucin-1 (MUC-1) is a high-molecular-weight glycoprotein rich in serine and threonine residues that are O-glycosylated. Expression… Expand
Review
2003
Review
2003
Clinical development of the STn-KLH vaccine (Theratope).
The development of active specific immunotherapy depends on the identification of altered cancer cell-specific molecules or… Expand
2003
2003
The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
The success of high-dose chemotherapy followed by autologous stem-cell rescue as treatment for breast and ovarian cancer is… Expand
Review
2003
Review
2003
Immunotherapy: new options in breast cancer treatment
Immunotherapy is a promising new approach in breast cancer treatment, complementing surgery, chemotherapy, radiation and… Expand
Review
2001
Review
2001
Theratope® vaccine (STn-KLH)
Active specific immunotherapy (ASI) is a promising approach to treating cancer. Numerous studies in the laboratory have… Expand
Highly Cited
2000
Highly Cited
2000
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine
The purpose of this study was to evaluate the toxicity and potential efficacy of administering the THERATOPE® STn-KLH cancer… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Review
2000
Review
2000
Technology evaluation: Theratope, Biomira Inc.
  • M. Morse
  • Current opinion in molecular therapeutics
  • 2000
    • Corpus ID: 39168794
Active specific immunotherapy, the use of 'vaccines' to stimulate therapeutic tumor antigen-specific immune responses, holds… Expand
Highly Cited
1996
Highly Cited
1996
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
THERATOPE (Biomira Inc., Edmonton, AB, Canada) STn-KLH cancer vaccine induces strong antibody titers against both the synthetic… Expand
Highly Cited
1996
Highly Cited
1996
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy
Abstract Patients with metastatic breast, colorectal or ovarian cancers received active specific immunotherapy (ASI) with… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE